AstraZeneca reported its largest quarterly revenue ever, as soaring sales of cancer drugs helped the drugmaker beat ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney ...

Core earnings rose 12% to $2.38 per share for the three months ended September 30, topping expectations of $2.29 per share. Revenue grew 10% at constant exchange rates to $15.19 billion, also ahead of ...

(Reuters) -AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on ...

British pharmaceutical giant AstraZeneca on Thursday said its net profit jumped 77 percent in the third quarter as the group expands its operations in the United States.

AstraZeneca has seen its fair value per share revised upward from $140.96 to $144.38. This change reflects growing analyst ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

In the third quarter, Oncology revenue rose 18% to USD6.64 billion, Cardiovascular, Renal & Metabolism sales were flat at USD3.22 billion, R&I grew 14% to USD2.26 billion, BioPharmaceuticals firmed 4% ...

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving ...